Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2

Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2

Although oxaliplatin is an effective chemotherapeutic drug commonly used for colorectal cancer (CRC) treatment, drug resistance usually occurs during the long-term use of it. It is urgent to create strategies to reduce the resistance of CRC cells to oxaliplatin. Oxaliplatin-resistant CRC cells (OR-S...

Full description

Bibliographic Details
Main Authors: Wei Sun, Yang Ge, Junpeng Cui, Yifan Yu, Baolin Liu
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Molecular Therapy: Oncolytics
Subjects:
oxaliplatin
colorectal cancer
pyruvate kinase isoenzyme M2
adenosine triphosphate
resistance
glucose
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770521000437

Internet

http://www.sciencedirect.com/science/article/pii/S2372770521000437

Similar Items